Publications by authors named "David A Wohl"

Claim this Profile
I
Implementing a Social Work-Led Hepatitis C Treatment Model for Individuals with Substance Use Disorders in Primary Care.
Aimee Kresica, Katherine McDougal, Jessica Waters Davis, Xiaoming Zeng, David Alain Wohl

J Evid Based Soc Work (2019)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A community and clinical collaboration to optimize HIV treatment and care for people with HIV in Australia-Solutions from the Beyond Undetectable symposium.
Mark O'Reilly, David Alain Wohl, Shauna Hall, Emil John Pastor Canĩta, Melania Mugamu

HIV Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research protocol design and implementation of a hybrid no-touch and low-touch prospective observational study during the COVID-19 public health emergency: the VISION study.
Becky Straub, Katie R Mollan, Jessica R Keys, Chanhwa Lee, Ronald Swanstrom, David A Wohl

BMJ Public Health· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy.
Rinki Deo, Manish C Choudhary, Owen T Glover, Rachel Bender Ignacio, Julie Boucau, David Alain Wohl

Open Forum Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease.
Jonathan Moses, Jeremy Adler, Shehzad A Saeed, Ann M Firestine, Joseph A Galanko, David A Wohl

Inflamm Bowel Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial.
Mark J Giganti, Kara W Chew, Carlee Moser, Joseph J Eron, Mauricio Pinilla, David Alain Wohl

Contemp Clin Trials· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.
Rachel A Bender Ignacio, Kara W Chew, Carlee Moser, Judith S Currier, Joseph J Eron, David Alain Wohl

iScience· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.
Kara W Chew, Brooke McGinley, Carlee Moser, Jonathan Z Li, Teresa H Evering, David A Wohl

J Infect Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocol.
Suzanne Penfold, Ayola Akim Adegnika, Danny Asogun, Olufemi Ayodeji, Benedict N Azuogu, David A Wohl

PLoS One· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health and economic impacts of Lassa vaccination campaigns in West Africa.
David R M Smith, Joanne Turner, Patrick Fahr, Lauren A Attfield, Paul R Bessell, David A Wohl

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.
Kara W Chew, Babafemi O Taiwo, Carlee Moser, Eric S Daar, David Alain Wohl

J Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.
Nathaniel Bloom, Sydney I Ramirez, Hallie Cohn, Urvi M Parikh, Amy Heaps, David A Wohl

J Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretrovirals and Weight Change: Weighing the Evidence.
David Alain Wohl, John R Koethe, Paul E Sax, Grace A McComsey, Daniel R Kuritzkes

Clin Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort.
Nell G Bond, Kayla R Shore, Emily J Engel, Erin E Coonan, Foday Al-Hasan, David A Wohl

J Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative.
David A Wohl, Stacey J Adam, Kevin W Gibbs, Ari L Moskowitz, Thomas L Ortel

J Clin Transl Sci· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building Clinical Care Capacity for Patients With Special Pathogens in Advance of the Next Outbreak.
Lauren Wiesner, Jade Flinn, Brooke Brewer, Aaron Resnick, Sharon Vanairsdale Carrasco, David A Wohl

Health Secur· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Teresa H Evering, Carlee Moser, Nikolaus Jilg, Justin Ritz, David A Wohl

EClinicalMedicine· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
Manish C Choudhary, Rinki Deo, Teresa H Evering, Kara W Chew, Mark J Giganti, David Alain Wohl

J Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
David A Wohl, Christoph D Spinner, Jason Flamm, C Bradley Hare, Susanne Doblecki-Lewis

Lancet HIV· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining vaccines, optimised supportive care, and therapeutics for Ebola virus disease increases survival.
William A Fischer, David A Wohl

Lancet Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
Dawn R Ebach, Traci W Jester, Joseph A Galanko, Ann M Firestine, Rana Ammoury, David A Wohl

Am J Gastroenterol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health and economic impacts of Lassa vaccination campaigns in West Africa.
David R M Smith, Joanne Turner, Patrick Fahr, Lauren A Attfield, Paul R Bessell, David A Wohl

medRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.
Katya C Corado, Kara W Chew, Mark J Giganti, Ying Mu, Courtney V Fletcher, David A Wohl

Pathog Immun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
Heather I Henderson, David A Wohl, William A Fischer, Luther A Bartelt, David van Duin

J Antimicrob Chemother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
Tin Phan, Carolin Zitzmann, Kara W Chew, Davey M Smith, Eric S Daar, David A Wohl

PLoS Pathog· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis